EA8153: Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
We would like to rely on the NCI CIRB as the IRB of record for this study.
The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone based therapy abiraterone acetate (also known as Zytiga®) in combination with prednisone on patients with advanced prostate cancer that have already undergone treatment with hormone therapy and the chemotherapy drug docetaxel.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 830024
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
